GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast AS (OCSE:COLO B) » Definitions » EV-to-Revenue

Coloplast AS (OCSE:COLO B) EV-to-Revenue : 5.79 (As of Jun. 24, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Coloplast AS EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Coloplast AS's enterprise value is kr160,919 Mil. Coloplast AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was kr27,794 Mil. Therefore, Coloplast AS's EV-to-Revenue for today is 5.79.

The historical rank and industry rank for Coloplast AS's EV-to-Revenue or its related term are showing as below:

OCSE:COLO B' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.82   Med: 8.4   Max: 13.12
Current: 5.79

During the past 13 years, the highest EV-to-Revenue of Coloplast AS was 13.12. The lowest was 5.82. And the median was 8.40.

OCSE:COLO B's EV-to-Revenue is ranked worse than
70.94% of 819 companies
in the Medical Devices & Instruments industry
Industry Median: 3.1 vs OCSE:COLO B: 5.79

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-24), Coloplast AS's stock price is kr609.60. Coloplast AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was kr123.39. Therefore, Coloplast AS's PS Ratio for today is 4.94.


Coloplast AS EV-to-Revenue Historical Data

The historical data trend for Coloplast AS's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast AS EV-to-Revenue Chart

Coloplast AS Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.57 11.13 8.10 7.62 8.10

Coloplast AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.15 8.06 8.10 7.32 6.71

Competitive Comparison of Coloplast AS's EV-to-Revenue

For the Medical Instruments & Supplies subindustry, Coloplast AS's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coloplast AS's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Coloplast AS's EV-to-Revenue falls into.


;
;

Coloplast AS EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Coloplast AS's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=160918.599/27794
=5.79

Coloplast AS's current Enterprise Value is kr160,919 Mil.
Coloplast AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr27,794 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coloplast AS  (OCSE:COLO B) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Coloplast AS's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=609.60/123.391
=4.94

Coloplast AS's share price for today is kr609.60.
Coloplast AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr123.39.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coloplast AS EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Coloplast AS's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Coloplast AS Business Description

Address
Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast AS Headlines

No Headlines